Astera Labs, Inc. $ALAB Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers raised its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 167.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,131 shares of the company’s stock after acquiring an additional 5,712 shares during the quarter. Cetera Investment Advisers’ holdings in Astera Labs were worth $826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ALAB. Vanguard Group Inc. raised its holdings in shares of Astera Labs by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 9,297,476 shares of the company’s stock worth $554,780,000 after purchasing an additional 85,846 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Astera Labs by 114.2% in the first quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock valued at $501,289,000 after buying an additional 4,478,741 shares in the last quarter. Atreides Management LP lifted its position in shares of Astera Labs by 153.3% during the 1st quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock valued at $277,601,000 after acquiring an additional 2,815,614 shares during the last quarter. Fred Alger Management LLC lifted its position in shares of Astera Labs by 13.0% during the 1st quarter. Fred Alger Management LLC now owns 1,560,033 shares of the company’s stock valued at $93,087,000 after acquiring an additional 179,638 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Astera Labs by 36.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,244,978 shares of the company’s stock worth $112,562,000 after acquiring an additional 330,841 shares in the last quarter. Institutional investors own 60.47% of the company’s stock.

Insider Buying and Selling at Astera Labs

In other news, General Counsel Philip Mazzara sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $192.16, for a total value of $1,921,600.00. Following the transaction, the general counsel directly owned 151,573 shares of the company’s stock, valued at approximately $29,126,267.68. This represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Sanjay Gajendra sold 90,459 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $13,088,512.71. Following the sale, the chief operating officer owned 1,599,750 shares of the company’s stock, valued at approximately $231,467,827.50. This represents a 5.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 586,936 shares of company stock worth $89,331,140 over the last 90 days. 12.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus boosted their target price on Astera Labs from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley restated an “overweight” rating and set a $210.00 price objective on shares of Astera Labs in a report on Wednesday. Barclays reiterated an “equal weight” rating and issued a $155.00 target price on shares of Astera Labs in a report on Monday, October 20th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Astera Labs from $160.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Finally, Northland Securities set a $175.00 price target on shares of Astera Labs in a research report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $187.06.

Astera Labs Price Performance

Shares of ALAB opened at $161.23 on Friday. The company has a market capitalization of $27.23 billion, a price-to-earnings ratio of 145.25, a P/E/G ratio of 2.84 and a beta of 1.51. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The business’s 50-day moving average is $170.02 and its 200-day moving average is $150.72.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.39 by $0.10. The business had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The firm’s quarterly revenue was up 103.9% compared to the same quarter last year. During the same period last year, the company posted $0.23 earnings per share. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Equities research analysts expect that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.